PCM
NTLA icon

Prelude Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Prelude Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,457
Closed -$136K – 1307
2025
Q2 		$136K Sell
14,457
-3,360
-19% -$27.6K 0.01% 869
2025
Q1 		$127K Buy
+17,817
New +$180K 0.01% 1016

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's NTLA Position: Q3 2025 in Review

Prelude Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 14,457 shares — an estimated $136K sold.

Prelude Capital Management first reported a position in NTLA in Q1 2025 and held it in 2 quarters. The position peaked at $136K in Q2 2025. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Prelude Capital Management reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 14,457 Intellia Therapeutics shares in Q3 2025, an estimated $136K.
  • Prelude Capital Management first reported a position in Intellia Therapeutics in Q1 2025 and held it in 2 quarters.
  • Prelude Capital Management's Intellia Therapeutics position peaked at $136K in Q2 2025.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.